{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T05:09:09Z","timestamp":1793250549557,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Vor Biopharma"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1038\/s41591-026-04362-1","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T09:03:41Z","timestamp":1778576621000},"page":"1763-1772","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["CRISPR\u2212Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1\/2 trial"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0429-3133","authenticated-orcid":false,"given":"John F.","family":"DiPersio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6281-4655","authenticated-orcid":false,"given":"Guenther","family":"Koehne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8474-9080","authenticated-orcid":false,"given":"Nirali N.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9a","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung C.","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Koura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2386-0850","authenticated-orcid":false,"given":"Roni","family":"Tamari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Umair","family":"Mushtaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Maakaron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Rimando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa E.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9949-3615","authenticated-orcid":false,"given":"Sagar S.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Hudson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Loken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"Slapak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah M.","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren A.","family":"Stanizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa M.","family":"Lee-Sundlov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjana","family":"Thosar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Mundelboim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangwu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanying Gary","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin E.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Xavier-Ferrucio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon L.","family":"Hyzy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9297-2855","authenticated-orcid":false,"given":"Michelle I.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen D.","family":"Raffel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda W.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"4362_CR1","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.annonc.2020.02.018","volume":"31","author":"M Heuser","year":"2020","unstructured":"Heuser, M. et al. Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 31, 697\u2013712 (2020).","journal-title":"Ann. Oncol."},{"key":"4362_CR2","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner, H. et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140, 1345\u20131377 (2022).","journal-title":"Blood"},{"key":"4362_CR3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1200\/JCO.2015.63.3826","volume":"34","author":"D Araki","year":"2016","unstructured":"Araki, D. et al. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission? J. Clin. Oncol. 34, 329\u2013336 (2016).","journal-title":"J. Clin. Oncol."},{"key":"4362_CR4","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1038\/s41409-021-01450-3","volume":"56","author":"AM Jimenez Jimenez","year":"2021","unstructured":"Jimenez Jimenez, A. M. et al. An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. Bone Marrow Transplant. 56, 3068\u20133077 (2021).","journal-title":"Bone Marrow Transplant."},{"key":"4362_CR5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1182\/blood.2021012412","volume":"141","author":"Z DeFilipp","year":"2023","unstructured":"DeFilipp, Z. & Chen, Y. B. How I treat with maintenance therapy after allogeneic HCT. Blood 141, 39\u201348 (2023).","journal-title":"Blood"},{"key":"4362_CR6","first-page":"2289","volume":"108","author":"J Senapati","year":"2023","unstructured":"Senapati, J., Kadia, T. M. & Ravandi, F. Maintenance therapy in acute myeloid leukemia: advances and controversies. Haematologica 108, 2289\u20132304 (2023).","journal-title":"Haematologica"},{"key":"4362_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.39","volume":"4","author":"A Ehninger","year":"2014","unstructured":"Ehninger, A. et al. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. Blood Cancer J. 4, e218 (2014).","journal-title":"Blood Cancer J."},{"key":"4362_CR8","doi-asserted-by":"publisher","first-page":"4086","DOI":"10.1182\/blood-2005-03-1072","volume":"106","author":"DC Taussig","year":"2005","unstructured":"Taussig, D. C. et al. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood 106, 4086\u20134092 (2005).","journal-title":"Blood"},{"key":"4362_CR9","unstructured":"MYLOTARG (gemtuzumab ozogamicin) for injection, for intravenous use (package insert) (Pfizer, 2025)."},{"key":"4362_CR10","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1002\/cncr.21326","volume":"104","author":"RA Larson","year":"2005","unstructured":"Larson, R. A. et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 104, 1442\u20131452 (2005).","journal-title":"Cancer"},{"key":"4362_CR11","doi-asserted-by":"publisher","first-page":"7164s","DOI":"10.1158\/1078-0432.CCR-1004-0018","volume":"11","author":"E Roman","year":"2005","unstructured":"Roman, E. et al. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia. Clin. Cancer Res. 11, 7164s\u20137170s (2005).","journal-title":"Clin. Cancer Res."},{"key":"4362_CR12","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.bbmt.2016.01.019","volume":"22","author":"S Zahler","year":"2016","unstructured":"Zahler, S. et al. A phase I study of reduced-intensity conditioning and allogeneic stem cell transplantation followed by dose escalation of targeted consolidation immunotherapy with gemtuzumab ozogamicin in children and adolescents with CD33+ acute myeloid leukemia. Biol. Blood Marrow Transplant. 22, 698\u2013704 (2016).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"4362_CR13","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","volume":"173","author":"MY Kim","year":"2018","unstructured":"Kim, M. Y. et al. Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia. Cell 173, 1439\u20131453 (2018).","journal-title":"Cell"},{"key":"4362_CR14","doi-asserted-by":"publisher","first-page":"11978","DOI":"10.1073\/pnas.1819992116","volume":"116","author":"F Borot","year":"2019","unstructured":"Borot, F. et al. Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies. Proc. Natl Acad. Sci. USA 116, 11978\u201311987 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4362_CR15","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41375-018-0277-8","volume":"33","author":"O Humbert","year":"2019","unstructured":"Humbert, O. et al. Engineering resistance to CD33-targeted immunotherapy in normal hematopoiesis by CRISPR\/Cas9-deletion of CD33 exon 2. Leukemia 33, 762\u2013808 (2019).","journal-title":"Leukemia"},{"key":"4362_CR16","unstructured":"Genome Aggregation Database (gnomAD). Deletion (4 Bases): 19-51729103-CCCGG-C (GRCh37); http:\/\/www.gnomad-sg.org\/variant\/19-51729103-CCCGG-C?dataset=gnomad_r2_1"},{"key":"4362_CR17","doi-asserted-by":"publisher","first-page":"e1011600","DOI":"10.1371\/journal.pgen.1011600","volume":"21","author":"J Dominy","year":"2025","unstructured":"Dominy, J. et al. Human CD33 deficiency is associated with mild alteration of circulating white blood cell counts. PLoS Genet. 21, e1011600 (2025).","journal-title":"PLoS Genet."},{"key":"4362_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2023.101135","volume":"31","author":"JR Lydeard","year":"2023","unstructured":"Lydeard, J. R. et al. Development of a gene edited next-generation hematopoietic cell transplant to enable acute myeloid leukemia treatment by solving off-tumor toxicity. Mol. Ther. Methods Clin. Dev. 31, 101135 (2023).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"4362_CR19","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1200\/JCO.21.02293","volume":"40","author":"L Luznik","year":"2022","unstructured":"Luznik, L. et al. Randomized phase III BMT CTN trial of calcineurin inhibitor-free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies. J. Clin. Oncol. 40, 356\u2013368 (2022).","journal-title":"J. Clin. Oncol."},{"key":"4362_CR20","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1200\/JCO.2016.71.2513","volume":"35","author":"JK Lamba","year":"2017","unstructured":"Lamba, J. K. et al. CD33 splicing polymorphism determines gemtuzumab ozogamicin response in de novo acute myeloid leukemia: report from randomized phase III Children\u2019s Oncology Group Trial AAML0531. J. Clin. Oncol. 35, 2674\u20132682 (2017).","journal-title":"J. Clin. Oncol."},{"key":"4362_CR21","unstructured":"U.S. Food & Drug Administration. FDA Briefing Document. Oncologic Drugs Advisory Committee Meeting July 11, 2017. BLA 761060 Mylotarg (gemtuzumab ozogamicin) https:\/\/www.fda.gov\/media\/106500\/download (2017)."},{"key":"4362_CR22","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1200\/JCO.23.02474","volume":"42","author":"MJ Levis","year":"2024","unstructured":"Levis, M. J. et al. Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3. J. Clin. Oncol. 42, 1766\u20131775 (2024).","journal-title":"J. Clin. Oncol."},{"key":"4362_CR23","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.bbmt.2016.12.633","volume":"23","author":"P Barba","year":"2017","unstructured":"Barba, P. et al. Ex vivo CD34+-selected T cell-depleted peripheral blood stem cell grafts for allogeneic hematopoietic stem cell transplantation in acute leukemia and myelodysplastic syndrome Is associated with low incidence of acute and chronic graft-versus-host disease and high treatment response. Biol. Blood Marrow Transplant. 23, 452\u2013458 (2017).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"4362_CR24","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1080\/10428194.2016.1265113","volume":"58","author":"JD Goldberg","year":"2017","unstructured":"Goldberg, J. D. et al. Early recovery of T-cell function predicts improved survival after T-cell depleted allogeneic transplant. Leuk. Lymphoma 58, 1859\u20131871 (2017).","journal-title":"Leuk. Lymphoma"},{"key":"4362_CR25","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/s41409-024-02474-1","volume":"60","author":"T Meyer","year":"2025","unstructured":"Meyer, T. et al. Immunological reconstitution and infections after alloHCT - a comparison between post-transplantation cyclophosphamide, ATLG and non-ATLG based GvHD prophylaxis. Bone Marrow Transplant. 60, 286\u2013296 (2025).","journal-title":"Bone Marrow Transplant."},{"key":"4362_CR26","first-page":"S308","volume":"26","author":"RJ O\u2019Reilly","year":"2020","unstructured":"O\u2019Reilly, R. J. et al. Host T-cells contribute to immune reconstitution and improved outcome in recipients of CD34 selected T-cell depleted allografts (TCD HCT) with full hematopoietic cell but persistent mixed T-cell chimerism. Transplant. Cell Ther. 26, S308 (2020).","journal-title":"Transplant. Cell Ther."},{"key":"4362_CR27","doi-asserted-by":"publisher","first-page":"780e1","DOI":"10.1016\/j.jtct.2021.05.020","volume":"27","author":"G Llaurador","year":"2021","unstructured":"Llaurador, G. et al. Donor-host lineage-specific chimerism monitoring and analysis in pediatric patients following allogeneic stem cell transplantation: influence of pretransplantation variables and correlation with post-transplantation outcomes. Transplant. Cell. Ther. 27, 780e1\u2013780e14 (2021).","journal-title":"Transplant. Cell. Ther."},{"key":"4362_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49883-w","volume":"15","author":"Y Kim","year":"2024","unstructured":"Kim, Y. et al. Terminal deoxynucleotidyl transferase and CD84 identify human multi-potent lymphoid progenitors. Nat. Commun. 15, 5910 (2024).","journal-title":"Nat. Commun."},{"key":"4362_CR29","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41589-021-00769-8","volume":"17","author":"TB Loveless","year":"2021","unstructured":"Loveless, T. B. et al. Lineage tracing and analog recording in mammalian cells by single-site DNA writing. Nat. Chem. Biol. 17, 739\u2013747 (2021).","journal-title":"Nat. Chem. Biol."},{"key":"4362_CR30","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1002\/(SICI)1521-4141(199911)29:11<3440::AID-IMMU3440>3.0.CO;2-C","volume":"29","author":"T Ulyanova","year":"1999","unstructured":"Ulyanova, T., Blasioli, J., Woodford-Thomas, T. A. & Thomas, M. L. The sialoadhesin CD33 is a myeloid-specific inhibitory receptor. Eur. J. Immunol. 29, 3440\u20133449 (1999).","journal-title":"Eur. J. Immunol."},{"key":"4362_CR31","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/j.1749-6632.2011.06449.x","volume":"1253","author":"PR Crocker","year":"2012","unstructured":"Crocker, P. R., McMillan, S. J. & Richards, H. E. CD33-related siglecs as potential modulators of inflammatory responses. Ann. N. Y. Acad. Sci. 1253, 102\u2013111 (2012).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"4362_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59713-2","volume":"16","author":"F Borot","year":"2025","unstructured":"Borot, F. et al. Multiplex base editing to protect from CD33 directed drugs for immune and gene therapy. Nat. Commun. 16, 4899 (2025).","journal-title":"Nat. Commun."},{"key":"4362_CR33","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41586-023-06496-5","volume":"621","author":"G Casirati","year":"2023","unstructured":"Casirati, G. et al. Epitope editing enables targeted immunotherapy of acute myeloid leukaemia. Nature 621, 404\u2013414 (2023).","journal-title":"Nature"},{"key":"4362_CR34","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/s41586-024-07456-3","volume":"630","author":"S Garaude","year":"2024","unstructured":"Garaude, S. et al. Selective haematological cancer eradication with preserved haematopoiesis. Nature 630, 728\u2013735 (2024).","journal-title":"Nature"},{"key":"4362_CR35","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s00277-014-2229-3","volume":"94","author":"M Koren-Michowitz","year":"2015","unstructured":"Koren-Michowitz, M. et al. Salvage therapy with ARA-C and gemtuzumab ozogamicin in AML patients relapsing after stem cell transplantation. Ann. Hematol. 94, 375\u2013378 (2015).","journal-title":"Ann. Hematol."},{"key":"4362_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00764-9","volume":"12","author":"M Jentzsch","year":"2022","unstructured":"Jentzsch, M. et al. Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation. Blood Cancer J. 12, 170 (2022).","journal-title":"Blood Cancer J."},{"key":"4362_CR37","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1182\/blood-2018-02-832360","volume":"131","author":"SO Ciurea","year":"2018","unstructured":"Ciurea, S. O. et al. Prognostic factors influencing survival after allogeneic transplantation for AML\/MDS patients with TP53 mutations. Blood 131, 2989\u20132992 (2018).","journal-title":"Blood"},{"key":"4362_CR38","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/j.1365-2141.2008.07153.x","volume":"143","author":"P Chevallier","year":"2008","unstructured":"Chevallier, P. et al. Persistence of CD33 expression at relapse in CD33+ acute myeloid leukaemia patients after receiving Gemtuzumab in the course of the disease. Br. J. Haematol. 143, 744\u2013746 (2008).","journal-title":"Br. J. Haematol."},{"key":"4362_CR39","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/jcph.1730","volume":"61","author":"JE Maakaron","year":"2021","unstructured":"Maakaron, J. E., Rogosheske, J., Long, M., Bachanova, V. & Mims, A. S. CD33-targeted therapies: beating the disease or beaten to death? J. Clin. Pharmacol. 61, 7\u201317 (2021).","journal-title":"J. Clin. Pharmacol."},{"key":"4362_CR40","doi-asserted-by":"crossref","unstructured":"Dohner, H. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129, 424\u2013447 (2017).","DOI":"10.1182\/blood-2016-08-733196"},{"key":"4362_CR41","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/nbt.3290","volume":"33","author":"A Hendel","year":"2015","unstructured":"Hendel, A. et al. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat. Biotechnol. 33, 985\u2013989 (2015).","journal-title":"Nat. Biotechnol."},{"key":"4362_CR42","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","volume":"22","author":"AC Harris","year":"2016","unstructured":"Harris, A. C. et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium. Biol. Blood Marrow Transplant. 22, 4\u201310 (2016).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"4362_CR43","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia, M. H. et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol. Blood Marrow Transplant. 21, 389\u2013401 (2015).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"4362_CR44","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1177\/00912700122012751","volume":"41","author":"JA Dowell","year":"2001","unstructured":"Dowell, J. A., Korth-Bradley, J., Liu, H., King, S. P. & Berger, M. S. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J. Clin. Pharmacol. 41, 1206\u20131214 (2001).","journal-title":"J. Clin. Pharmacol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04362-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04362-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04362-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T14:03:36Z","timestamp":1779285816000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04362-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["4362"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04362-1","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"1 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.F.D.: equity and research funding from Wugen, Magenta Therapeutics and RiverVest Venture Partners; board member or advisory role for SPARC and Vertex; and research funding from NeoImmune Tech, Macrogenics and Bioline. G.K.: consultancy for Vor Biopharma. N.N.S.: research funding from Lentigen, Vor Biopharma and ImmunoACT Sobi; advisory board for Vor Biopharma (unpaid); and royalities from CARGO. D.K.: advisory board for Bristol Myers Squibb and research funding from Iovance Biotherapeutics. J.M.: research funding from Gilead, Atara, CRISPR Therapeutics, Precision Biosciences, Scripps Research Institute, Vor Biopharma and Affimed. V.E.K.: consultancy for Astelles and Servier. S.S.P.: advisory board for CareDx and Sobi; advisory board and speaker for Sanofi; and speakeer for Kite and Incyte. L.B., H.C.S., R.T., J.R. and B.W.C. report no conflicts of interest. C.H. and M.L. are employees of Hematologics. C.A.S., D.M.L., D.A.S., M.M.L.-S., S.T., G.M., G.G., H.G.G., B.E.L., J.X.-F., S.L.H., M.I.L. and G.D.R. were employees of Vor Biopharma when the work was conducted.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}